Physician
Aldallal, Nada
Aldallal, Nada was paid $9.48M by Medicaid between Jan 2018 and Dec 2024, across 95 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 28% of everything it billed.
33Billing provider infoALDALLAL, NADA
CHICAGO, IL 60609
CHICAGO, IL 60609
33aNPI1346314564assigned 11/20/2006
33bProvider typePediatrics Physician
28Total paid$9.48M
24GClaims224,263
24DCodes billed95
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Illinois
Rank by total paid#3 of 1,805
Median peer was paid$55K
This provider vs. median172×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,171 | $655K | |
| 2019 | 28,281 | $892K | |
| 2020 | 30,323 | $1.05M | |
| 2021 | 32,904 | $1.37M | |
| 2022 | 44,609 | $2.17M | |
| 2023 | 32,346 | $1.54M | |
| 2024incomplete | 35,629 | $1.79M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 28% | 33,225 | 24,089 | $2.62M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 25% | 47,909 | 33,590 | $2.36M |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 5.3% | 9,732 | 7,542 | $507K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 5.3% | 1,450 | 1,116 | $505K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 5.2% | 5,930 | 5,050 | $496K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.5% | 5,666 | 4,556 | $427K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.9% | 7,095 | 5,602 | $369K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 3.1% | 3,851 | 3,004 | $294K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 2.4% | 14,007 | 11,418 | $225K |
| Q3014 | Telehealth originating site facility fee | 2.0% | 7,621 | 5,554 | $188K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.5% | 5,955 | 4,984 | $142K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.0% | 1,146 | 959 | $97K |
83 more codes
| 90686 | <1% | 9,077 | $92K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 1,308 | $91K |
| 99000 | <1% | 3,843 | $85K | |
| 96160 | <1% | 5,676 | $82K | |
| 96127 | <1% | 4,738 | $71K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,414 | $65K |
| 87486 | <1% | 1,335 | $60K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,183 | $56K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,119 | $50K |
| 90651 | <1% | 2,625 | $50K | |
| 87561 | <1% | 1,055 | $49K | |
| 94664 | <1% | 2,539 | $38K | |
| 90734 | <1% | 2,491 | $35K | |
| 90620 | <1% | 2,477 | $34K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,405 | $31K |
| 83655 | <1% | 2,143 | $25K | |
| 0001A | <1% | 498 | $21K | |
| 90670 | <1% | 1,339 | $20K | |
| 0071A | <1% | 461 | $20K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,230 | $19K |
| 0002A | <1% | 452 | $19K | |
| 0072A | <1% | 385 | $16K | |
| 99423 | <1% | 373 | $16K | |
| 0124A | <1% | 356 | $15K | |
| 81003 | <1% | 6,880 | $15K | |
| 90715 | <1% | 971 | $11K | |
| 90633 | <1% | 1,064 | $11K | |
| 0053A | <1% | 255 | $11K | |
| 87581 | <1% | 265 | $11K | |
| 81002 | <1% | 4,200 | $10K | |
| 90710 | <1% | 663 | $10K | |
| 36416 | <1% | 2,435 | $10K | |
| 90648 | <1% | 1,109 | $9K | |
| 90656 | <1% | 520 | $9K | |
| 0073A | <1% | 187 | $8K | |
| 85018 | <1% | 3,385 | $8K | |
| 0154A | <1% | 129 | $6K | |
| 90677 | <1% | 98 | $5K | |
| 90723 | <1% | 472 | $4K | |
| 90680 | <1% | 339 | $4K | |
| 0081A | <1% | 80 | $3K | |
| 99401 | <1% | 132 | $3K | |
| 99173 | <1% | 467 | $3K | |
| 86328 | <1% | 74 | $3K | |
| 0003A | <1% | 73 | $3K | |
| 99402 | <1% | 95 | $3K | |
| 91320 | <1% | 182 | $3K | |
| 0012A | <1% | 54 | $2K | |
| 82947 | <1% | 571 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 20 | $2K |
| 90716 | <1% | 84 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 24 | $2K |
| 0011A | <1% | 52 | $2K | |
| 86580 | <1% | 313 | $2K | |
| 90696 | <1% | 164 | $1K | |
| 90685 | <1% | 201 | $1K | |
| 90700 | <1% | 84 | $1K | |
| 90707 | <1% | 63 | $1K | |
| 91319 | <1% | 91 | $1K | |
| 0004A | <1% | 25 | $1K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 22 | $783.90 |
| 0082A | <1% | 14 | $601.92 | |
| 87807 | <1% | 58 | $589.54 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 13 | $423.96 |
| 93000 | <1% | 15 | $371.00 | |
| 69210 | <1% | 18 | $363.80 | |
| 91322 | <1% | 18 | $302.45 | |
| 90756 | <1% | 24 | $283.20 | |
| 90681 | <1% | 15 | $250.65 | |
| 99421 | <1% | 18 | $240.06 | |
| 82962 | <1% | 153 | $213.55 | |
| 81025 | <1% | 49 | $170.45 | |
| 91300 | <1% | 53 | $150.87 | |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 86 | $108.25 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,487 | $59.88 |
| 97802 | <1% | 21 | $12.00 | |
| 91308 | <1% | 26 | $0.02 | |
| A7004 | Small volume nonfiltered pneumatic nebulizer, disposable | 0% | 49 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 22 | $0.00 |
| 99443 | 0% | 13 | $0.00 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | 0% | 16 | $0.00 |
| 99072 | 0% | 66 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 77 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.